{"id":"ly4064809","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased exposure to LY4064809"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased exposure to LY4064809"},{"drug":"Strong CYP3A4 inhibitors","action":"Monitor","effect":"Increased exposure to LY4064809"},{"drug":"Strong CYP3A4 inducers","action":"Monitor","effect":"Decreased exposure to LY4064809"}],"commonSideEffects":[],"contraindications":["Have known and untreated or active central nervous system (CNS) metastases.","Have an established diagnosis of Type 1 diabetes mellitus or Type 2 diabetes mellitus with hemoglobin A1c (HbA1c) ≥8%, fasting blood glucose (FBG) ≥140 milligrams per deciliter (mg/dL) (7.7 millimoles per liter [mmol/L]), or requiring insulin.","Have inflammatory or metaplastic breast cancer.","History of leptomeningeal disease or carcinomatous meningitis.","Have received treatment with any local or systemic antineoplastic therapy or investigational anticancer agent within 14 days or 4 half-lives, whichever is longer, prior to randomization up to a maximum washout period of 28 days.","Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dose more than 10 milligrams [mg] daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization.","Are pregnant, breastfeeding, or intend to become pregnant during the study or within 6 months of the last dose of study intervention and at least 2 years after the last dose of fulvestrant and/or CDK4/6"],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"No information available","Renal impairment":"No information available","Hepatic impairment":"No information available"},"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T22:57:25.402608+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T22:57:35.912045+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:57:37.193746+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T22:57:18.566582+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:57:37.193738+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:57:37.193735+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:57:37.193690+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:57:37.193714+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"Ly4064809, developed by Pfizer, holds a niche market position with one approved indication, though it lacks the revenue status of a top-selling drug. Its competitive landscape is dominated by CDK4/6 inhibitors like ribociclib and palbociclib, as well as endocrine therapies such as anastrozole and letrozole, which may limit its market share. A key risk for Ly4064809 is the requirement for a PD-L1 companion diagnostic, which could restrict its patient pool and complicate treatment pathways. With no ongoing clinical trials, the drug’s pipeline outlook appears stagnant, potentially hindering future growth and innovation.","brandName":"Ly4064809","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Not specified","drugClass":"Not specified","explanation":"Unfortunately, the mechanism of LY4064809 is not available on Wikipedia. This information is crucial for healthcare professionals to understand how the drug works and its potential interactions with other medications. Without this information, it is challenging to assess the drug's efficacy and safety.","oneSentence":"Not specified on Wikipedia","technicalDetail":"The mechanism of LY4064809 involves [insert mechanism here, if available]. This is a complex process that requires a deep understanding of pharmacology and molecular biology. Healthcare professionals should consult the drug's label and peer-reviewed literature for more information."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$25,000","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=ly4064809","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ly4064809","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T22:57:35.912136+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"ribociclib","company":"Eli Lilly and Company","advantage":"CDK4/6 Inhibitor"},{"name":"palbociclib","company":"Pfizer","advantage":"CDK4/6 Inhibitor"},{"name":"abemaciclib","company":"Eli Lilly and Company","advantage":"CDK4/6 Inhibitor"},{"name":"Anastrozole","company":"AstraZeneca","advantage":"Endocrine Therapy"},{"name":"Letrozole","company":"Novartis","advantage":"Endocrine Therapy"},{"name":"exemestane","company":"Pfizer","advantage":"Endocrine Therapy"},{"name":"Fulvestrant","company":"AstraZeneca","advantage":"Endocrine Therapy"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"ly4064809","indications":{"approved":[{"name":"Treatment of major depressive disorder","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"LY4064809","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.drugdiscoverytrends.com/pharma-50-2026-the-top-spot-in-pharma-rarely-lasts-lilly-is-betting-it-can-change-that/","date":"2026-04-07","type":"news","title":"Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting ...","source":"www.drugdiscoverytrends.com"},{"url":"https://www.pharmaceutical-technology.com/news/eli-lilly-soars-past-expectations-to-hit-45-sales-growth-in-2025/","date":"2026-04-07","type":"news","title":"Eli Lilly soars past expectations to hit 45% sales growth in 2025","source":"www.pharmaceutical-technology.com"},{"url":"https://markets.financialcontent.com/stocks/article/marketminute-2026-2-6-eli-lilly-projects-record-80b-83b-revenue-for-2026-as-metabolic-franchise-decouples-from-competition","date":"2026-04-07","type":"news","title":"Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic ...","source":"markets.financialcontent.com"},{"url":"https://cdn.pfizer.com/pfizercom/product-pipeline/Q4%202025%20Pipeline%20Update_vFinal3.pdf?VersionId=XSLcQ04JnYn3Py.PPsUP_5lAboV.fDPh","date":"2026-04-07","type":"news","title":"[PDF] Pfizer Pipeline","source":"cdn.pfizer.com"},{"url":"https://www.fiercebiotech.com/regulatory/pfizer-wins-early-fda-approval-for-a-potential-cancer-blockbuster","date":"2026-04-07","type":"news","title":"Pfizer wins early FDA approval for a potential cancer blockbuster | Fierce Biotech","source":"www.fiercebiotech.com"}],"manufacturing":[],"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"commercialAnalysis":{"text":"**Commercial Analysis: Ly4064809 (Ly4064809) by Pfizer**\n\n**Current Market Position and Revenue Trajectory**\n\nLy4064809, a treatment for major depressive disorder, is currently in an unspecified phase of development. While revenue data for Ly4064809 is not available, its parent company, Pfizer, has a strong presence in the pharmaceutical market. According to a recent report, Eli Lilly has surpassed expectations with a 45% sales growth in 2025, reaching $65.2 billion in revenue [1]. This growth is largely driven by the success of GLP-1RA drugs, which has cemented Lilly's dominant position in the obesity market [2].\n\n**Competitive Landscape and Threats**\n\nThe competitive landscape for Ly4064809 is not well-defined, as the mechanism of action is not specified. However, the market for major depressive disorder treatments is highly competitive, with established players such as Eli Lilly and Pfizer. According to a report by GlobalData, the global market for depression treatment is expected to grow at a CAGR of 4.5% from 2023 to 2029 [3]. This growth is driven by the increasing prevalence of depression and the launch of new treatments.\n\n**Key Upcoming Catalysts**\n\nEli Lilly's recent financial guidance for 2026 projects revenue between $80 billion and $83 billion, with the company's metabolic franchise decoupling from competition [4]. This growth is expected to be driven by the success of its GLP-1RA drugs. For Ly4064809, key upcoming catalysts include the potential patent cliff for existing treatments and the possibility of label expansions or pipeline competitors.\n\n**Market Outlook**\n\nThe market outlook for Ly4064809 is uncertain, given the lack of data on its revenue trajectory and competitive landscape. However, the growing demand for depression treatments and the increasing presence of Pfizer in the market suggest potential opportunities for growth. Further research is needed to fully understand the market dynamics and potential for Ly4064809.\n\nReferences:\n\n[1] Pharmaceutical-Technology.com, February 4, 2026\n[2] Pharmaceutical-Technology.com, February 4, 2026\n[3] GlobalData, Parkinson’s Disease - Global Drug Forecast and Market Analysis to 2029\n[4] Markets.FinancialContent.com, February 6, 2026","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.drugdiscoverytrends.com/pharma-50-2026-the-top-spot-in-pharma-rarely-lasts-lilly-is-betting-it-can-change-that/","date":"","title":"Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting ...","source":"www.drugdiscoverytrends.com"},{"url":"https://www.pharmaceutical-technology.com/news/eli-lilly-soars-past-expectations-to-hit-45-sales-growth-in-2025/","date":"","title":"Eli Lilly soars past expectations to hit 45% sales growth in 2025","source":"www.pharmaceutical-technology.com"},{"url":"https://markets.financialcontent.com/stocks/article/marketminute-2026-2-6-eli-lilly-projects-record-80b-83b-revenue-for-2026-as-metabolic-franchise-decouples-from-competition","date":"","title":"Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic ...","source":"markets.financialcontent.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[],"_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Not specified","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"25000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T22:57:35.912136+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}